Silence Therapeutics plc Files 8-K Report
Ticker: SLNCF · Form: 8-K · Filed: May 8, 2025 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 8-K |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
Silence Therapeutics filed an 8-K on May 8, 2025, reporting financial updates.
AI Summary
Silence Therapeutics plc filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details in the provided text, but indicates a formal reporting event.
Why It Matters
This 8-K filing signals that Silence Therapeutics plc is providing updated information regarding its financial condition and operational results to the SEC and the public.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not inherently present new risks, but rather reports on existing conditions.
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- May 8, 2025 (date) — Date of Report
- 72 Hammersmith Road London United Kingdom W14 8TH (address) — Principal executive offices
FAQ
What specific financial results are being reported by Silence Therapeutics plc in this 8-K?
The provided text of the 8-K filing does not contain specific financial figures or detailed results of operations. It only indicates that these items are being reported.
What is the primary purpose of this 8-K filing for Silence Therapeutics plc?
The primary purpose is to report on the company's Results of Operations and Financial Condition, and to file Financial Statements and Exhibits as required by the SEC.
When was this 8-K report filed with the SEC?
The report was filed on May 8, 2025.
What is the principal executive office address for Silence Therapeutics plc?
The principal executive office is located at 72 Hammersmith Road, London, United Kingdom, W14 8TH.
Does this filing indicate any significant changes in the company's structure or business?
The filing itself is a standard 8-K for reporting results and financial condition. It does not explicitly mention any significant changes in structure or business in the provided excerpt.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding Silence Therapeutics plc (SLNCF).